Coronavirus Resources


Stay up-to-date with the latest information from government agencies, NGOs, and other helpful organizations



Share what you need, and how you can help, to advance COVID-19 treatments, vaccines, and diagnostics


Services to support your company’s operations during this public health emergency

Biopharmaceutical Innovators Lead the Charge in Fight Against Coronavirus
Filter by Category:
AbbVie has partnered with global authorities to support the use of HIV medicines to treat COVID-19.
Aequor has advanced its "green" surface cleaners to stop the spread of COVID-19.
Alnylam Pharmaceuticals, Inc. has expanded its collaboration with Vir to advance RNAi therapeutics.
Arcturus is developing a COVID-19 candidate vaccine using STARR™ Technology.
Bayer is accelerating the availability of tests and is testing Resochin in treating patients with COVID-19 infection.    
Bellerophon is testing its INOpulse system to treat the novel coronavirus.
CSL is lending its expertise, technologies and facilities to help support rapid development of vaccines and treatments.
Dynavax is providing CpG 1018 to support the development of a COVID-19 vaccine.
EpiVax is identifying key regions of viral sequences to include in a COVID-19 vaccine.         
Genentech has initiated a Phase III clinical trial of Actemra in hospitalized patients with severe COVID-19 pneumonia.
GeoVax is using its GV-MVA-VLP vaccine platform to develop a vaccine for COVID-19.
Gilead has initiated two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir. 
Biotech Companies Are Responding Faster Than Ever to Emerging Health Threats
Biotech companies are responding faster than ever to emerging health threats
BIO Coronavirus Collaboration Initiative Summit

The Biotechnology Innovation Organization (BIO) virtually brought together 45 biotech innovators, government agencies, and leading academics to share information about their work to fight the coronavirus.

Dr. George Scangos Coronavirus Lead
Hear from BIO's Coronavirus Lead

George Scangos, Ph.D., President and Chief Executive Officer of Vir Biotechnology, has been selected to lead the Biotechnology Innovation Organization's response to Coronavirus (COVID-19). Dr. Scangos explains what this role means and why collaboration across the private, public and NGO sectors is vital in combating Coronavirus.

The Coronavirus Is No Match for Science, but We Must Finish the Job

Jim Greenwood in Morning Consult: The science is galloping forward, and collaboration between the public and private sectors is vital to combat the coronavirus. BIO is taking the lead to connect innovators with partners inside the federal government.

Biopharmaceutical Innovators Are Leading The Charge In Fight Against Coronavirus

Here's a snapshot of how our industry is responding to the coronavirus.

BIO Members Are Working Around The Clock To Find Solutions To Combat Coronavirus

Learn about how the biopharmaceutical industry is responding to the coronavirus.

BIO/ BioCentury Survey: COVID-19 Impact on Clinical Trials

A joint survey from BIO and BioCentury finds companies are seeking guidance and regulatory flexibility, while at the same time moving to remote monitoring and telemedicine for ongoing trials. 

Biotech Leaders Hit the Airwaves to Talk About Industry’s Efforts to Eradicate Covid-19

As the novel coronavirus continues to spread, scientists and researchers are working around the clock to identify diagnostics, therapeutics and vaccines to help protect individuals and communities across the globe.